Nanoparticle therapy for knee osteoarthritis
Treating knee osteoarthritis by sPLA2 inhibitor-loaded micellar nanoparticles
['FUNDING_R01'] · UNIVERSITY OF PENNSYLVANIA · NIH-11304555
Tiny carriers deliver an anti-inflammatory drug directly into the knee to help people with osteoarthritis feel less pain and protect their cartilage.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF PENNSYLVANIA (nih funded) |
| Locations | 1 site (PHILADELPHIA, UNITED STATES) |
| Trial ID | NIH-11304555 on ClinicalTrials.gov |
What this research studies
The team is developing micellar nanoparticles that carry an sPLA2-blocking drug aimed at reducing joint inflammation in knee osteoarthritis. In laboratory and animal tests they will check whether these particles remain in the joint longer and penetrate cartilage better than current treatments. Outcomes measured will include joint inflammation, cartilage damage, and joint function to see if the approach slows disease progression. If translated to human work, participants would likely be adults with knee osteoarthritis seen at the University of Pennsylvania.
Who could benefit from this research
Good fit: Adults with symptomatic knee osteoarthritis—especially those with early to mid-stage disease and ongoing pain despite standard treatments—would be the best fit.
Not a fit: People with very advanced, end-stage osteoarthritis already scheduled for joint replacement, those with knee pain from non-osteoarthritis causes, or those with allergies to nanoparticle components may not benefit.
Why it matters
Potential benefit: Could reduce joint inflammation and slow cartilage breakdown, potentially delaying or avoiding knee replacement surgery.
How similar studies have performed: Related nanoparticle and targeted anti-inflammatory approaches have shown promise in lab and animal studies but remain largely unproven in large human trials for osteoarthritis.
Where this research is happening
PHILADELPHIA, UNITED STATES
- UNIVERSITY OF PENNSYLVANIA — PHILADELPHIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CHENG, ZHILIANG — UNIVERSITY OF PENNSYLVANIA
- Study coordinator: CHENG, ZHILIANG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.